JavaScript seems to be disabled in your browser. For the best experience on our site, be sure to turn on Javascript in your browser.

Home
Signaling Pathways

Signaling Pathways

A8394 CHIR-124

Target: FLT3|GSK-3|Chk|PDGFR

Summary: Chk1 inhibitor,novel and potent

insoluble in H2O; ≥10.5 mg/mL
A8550 Telatinib (BAY 57-9352)

Target: VEGFR|PDGFR|c-Kit

Summary: VEGFR-2/-3,PDGFR-β and c-Kit inhibitor

insoluble in H2O; insoluble in EtOH; ≥20.5 mg/mL
B2172 PP121

Target: mTOR|Eph Receptors|VEGFR|PDGFR|Bcr-Abl|Src|DNA-PK|P110|Hck

Summary: Dual inhibitor of tyrosine and phosphoinositide kinases
B2173 CP-673451

Target: PDGFR

Summary: PDGFRα/β inhibitor,potent and selective
A8236 Regorafenib
4 Citation

Target: Raf|VEGFR|PDGFR|c-Kit|RET

Summary: Inhibitor of VEGFR/PDGFR/FGFR/mutant kit/RET/Raf-1

≥25.04 mg/mL
A8252 Nintedanib (BIBF 1120)
3 Citation

Target: VEGFR|PDGFR|FGFR

Summary: VEGFR/PDGFR/FGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥5.34 mg/mL
A2942 Masitinib (AB1010)

Target: PDGFR|c-Kit|Lyn

Summary: Tyrosine kinase inhibitor, potent and selective

≥24.95 mg/mL
A2949 Linifanib (ABT-869)

Target: VEGFR|PDGFR

Summary: VEGFR/PDGFR inhibitor

insoluble in H2O; insoluble in EtOH; ≥18.75 mg/mL
A1805 Imatinib Mesylate (STI571)

Target: PDGFR|c-Kit|Bcr-Abl

Summary: Abl/c-kit/PDGFR inhibitor

≥29.5 mg/mL
A2168 Dovitinib (TKI-258, CHIR-258)
2 Citation

Target: FLT3|VEGFR|PDGFR|c-Kit|FGFR

Summary: Multitargeted RTK inhibitor

insoluble in H2O; insoluble in EtOH; ≥36.35 mg/mL